10.1038/nrm3667 Nat
Coverage policies reflect the fact that compounded tirzepatide and other GLP-1 agents remain off-label for standalone weight loss treatment in most insurance frameworks
Summary Microdosing is typically treated as a tolerability-first, clinician-guided approach, involving starts below the usual 2.5 mg step, extending escalation windows from 4 to 8 weeks or more, or pausing at intermediate maintenance doses, such as 5 mg or 7.5 mg, to prioritize steady adherence and symptom control
Click the Subscribe button for details: Like this piece
231 utilized a chromatin immunoprecipitation (ChIP) assay to determine that the human adipose tissue H3K4me3 histone mark site in adipogenic, lipid metabolism, and inflammatory genes (such as LEP , LPL , SREBF2 , SCD1 , PPARG , IL6 , TNF , and E2F1 ) is positively associated with BMI and HOMA-IR
JCI Insight (2017) 2e93098